Navigation Links
Moffitt Cancer Center study validates activity of rare genetic variant in glioma
Date:7/2/2012

Researchers at Moffitt Cancer Center working with colleagues at three other institutions have validated a link between a rare genetic variant and the risk of glioma, the most common and lethal type of brain tumor. The validation study also uncovered an association between the same rare genetic variant and improved rates of survival for patients with glioma.

The study, the first to confirm a rare susceptibility variant in glioma, appeared in a recent issue of the Journal of Medical Genetics, a journal published by the British Medical Association.

"Glioma is a poorly understood cancer with high morbidity and devastating outcomes," said study lead author Kathleen M. Egan, Sc.D., interim program leader of Cancer Epidemiology and vice chair of the Department of Cancer Epidemiology. "However, the discovery of the association of the TP53 genetic variant rs78378222 with glioma provides new insights into these tumors and offers better prospects for identifying people at risk."

According to the authors, their study "genotyped' the single nucleotide polymorphism (SNP, or "snip") rs78378222 in TP53, an important tumor suppressor gene. The researchers said the SNP disrupts the TP53 signal and, because of its activity, has been linked to a variety of cancers. This study linked the presence of the rare form of rs78378222 to deadly glioma.

The researchers conducted a large, clinic-based, case-control study of individuals age 18 and older with a recent glioma diagnosis. A total of 566 glioma cases and 603 controls were genotyped for the rs78378222 variant.

Study results reveal that the odds of developing glioma were increased 3.5 times among the rare variant allele carriers. However, when researchers examined the impact of rs78378222 on survival, they found an approximately 50 percent reduction in death rates for those who were variant allele carriers.

"That the variant increased survival chances was an unexpected finding," Egan said. "It is tempting to speculate that the presence of the risk allele could direct tumor development into a less aggressive path."

The researchers concluded that their study results "may shed light on the etiology and progression of these tumors."

In addition to researchers from Moffitt, researchers from The University of Alabama at Birmingham, Emory School of Medicine and Vanderbilt University participated in the study and co-authored the paper.


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers find cutaneous human papillomavirus infection a risk factor for skin cancer
2. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
3. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
4. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
5. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
6. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
7. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
8. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
9. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
10. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
11. Moffitt researcher publishes book on nutritional management of cancer treatment effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the ... studies, the Center for Disease Control ( CDC ) and Infectious Diseases Society of ... Liegner, M.D. has compiled into a single volume a compelling argument that the disease ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, ... announce an upgrade to the company's Yelp listing. Bay Area residents struggling from ... diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular ...
(Date:2/26/2017)... Dublin, Ireland (PRWEB) , ... February 26, 2017 ... ... accreditation, as in 2011 the lab became the world’s first to be ISO/IEC ... d 1 (cat allergen) analysis. , ISO/IEC 17025:2005 is the globally recognised standard ...
(Date:2/26/2017)... KS (PRWEB) , ... February ... ... StaffBridge sets a new technology standard in staffing, scheduling, and reporting for ... monitor, and predict activity throughout the entire staffing process. StaffBridge technology improves ...
(Date:2/25/2017)... , ... February 25, 2017 , ... FCPX users now ... tools from Pixel Film Studios. With ProSharpen Color users have total control over sharpening ... refine their color range. With color spectrum tools users can visually see the color ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 LG Innotek hat heute die weltweit ... beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... 200 und 280 nm und eignet sich damit für Sterilisationsaufgaben. ... DNA zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung ... ...
(Date:2/23/2017)... Feb. 23, 2017 ITL Limited, ( ASX: ITD ), ... for the half year ended 31 December 2016 compared with the ... presentation can be viewed here . Highlights ... $1.04m; up 104%) Earnings per share of 2.2 ... of $17.5m (Dec 2015: $15.7m; up 11%) Profit ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research and ... and Strategies - 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis ... global Menopause market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Menopause market? ...
Breaking Medicine Technology: